In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IQWiG finds no added benefit for Dendreon's Provenge or Gilead's Zydelig

This article was originally published in Scrip

Executive Summary

There is no proven benefit for either Dendreon's prostate cancer treatment Provenge (Sipuleucel-T) or Gilead's Zydelig (idelalisib) for follicular lymphoma or chronic lymphocytic leukaemia, according to IQWiG, Germany's health technology appraisal body.

You may also be interested in...

UK Pulls Out Of Unified Patent Court Agreement

The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.

Brazil Issues Guidance For Clinical Trials Conducted During Pandemic

Brazil’s medicines regulator has published advice for developers on how to proceed with ongoing clinical trials and bioequivalence studies during the current COVID-19 pandemic.

Opaque Pricing Could Protect Europe From US Policy

Obscure drug pricing in Europe could help minimize an “access threat” posed by US pricing policies.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts